MONEONCT03979131
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 37 words Show 5 more changesShow less
- Study completion pushed from Jun 15, 2026 to Jun 15, 2027
- Secondary endpoints: details revised at 4 of 4 entries
- Study description expanded, about 8 words
- Site details revised
- Publications: details revised at 1 of 1 entry
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 37 to confirmed 40
- Primary completion date changed from estimate of Jan 15, 2023 to Mar 15, 2023
- Site details revised
- Notable Primary completion date: Jun 15, 2022 to Jan 15, 2023v5
- Notable Primary completion date: Jun 15, 2021 to Jun 15, 2022v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jun 15, 2019 to Aug 22, 2019
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Pathological complete response (pCR) rate
Timeframe: 7 years
Secondary (4)
Overall survival (OS)
Disease-free survival (DFS)
Progression-free survival (PFS)
Surgical complete resection rate (R0)
Arms and interventions
Resectable GC and GEJC+avelumab+FLOT preoperative treatmentExperimental
Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year.
Combination products: Avelumab addition to perioperative chemotherapy in GC and GEJC
Sites
1 site in 1 country
- Vall d'Hebron Institute of OncologyBarcelona, Spain